Inflammatory pain factors

Inflammatory pain factors refer to a diverse group of chemical mediators released by damaged tissues and immune cells during the inflammatory process that drive pain hypersensitivity [1, 6]. This 'inflammatory soup' consists of various molecules, including pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), lipid mediators (e.g., prostaglandins, leukotrienes), and peptides (e.g., bradykinin, nerve growth factor) [1, 6]. These factors act collectively to sensitize or directly activate peripheral sensory neurons (nociceptors) by binding to specific receptors and modulating ion channels like TRPV1 and Nav1.8, thereby lowering the threshold for pain transmission [5, 12]. Therapeutic interventions targeting these factors include non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit prostaglandin synthesis, and biologics that neutralize specific cytokines [10, 11]. Recent advancements have introduced multi-target approaches, such as the iPSC-derived nociceptor therapy SN101, which functions as a biological 'sponge' to sequester multiple inflammatory pain factors simultaneously, potentially offering a disease-modifying effect in conditions like osteoarthritis [2, 7, 9].

Other names

Inflammatory mediatorsPro-inflammatory cytokinesInflammatory soupNociceptive mediatorsPain-producing substances

Inhibition of mediator synthesis (e.g., COX inhibition), direct neutralization of cytokines by monoclonal antibodies, or sequestration of multiple factors by cellular 'sponges' to prevent nociceptor activation [2, 7, 10].